LAGUNA HILLS, Calif., November 16, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2026.
Adagio Medical (NASDAQ:ADGM) has begun a formal strategic review that could include a sale, merger or other transaction, while reducing its workforce and continuing to advance the U. S.
This is the newest page. Registered accounts read further back.